Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation.

@article{Cleland2005OncemonthlyAO,
  title={Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation.},
  author={John Gf Cleland and John T. Sullivan and Stephen Ball and John David Horowitz and Balaji Agoram and Dylan Rosser and Wayne Yates and Lwin Tin and Paulina Fuentealba and Paul Bryan Burton},
  journal={Journal of cardiovascular pharmacology},
  year={2005},
  volume={46 2},
  pages={155-61}
}
In patients with chronic heart failure (CHF), anemia is associated with more severe symptoms and worse prognosis. Erythropoiesis-stimulating proteins (ESPs) increase hemoglobin and may be of therapeutic benefit. We investigated the pharmacokinetics and pharmacodynamics of the long-acting ESP, darbepoetin alfa, administered on 2 occasions 1 month apart to 30… CONTINUE READING